Brain & Nerve Supplements: What the Evidence Shows

Enhancement versus protection: most supplements only have evidence for one

The single most important distinction in this category — and the one most consistently ignored in marketing — is the difference between cognitive enhancement in healthy adults and cognitive protection or slowing of decline in at-risk populations.

Cognitive enhancement means improving memory, processing speed, or executive function beyond normal baselines in healthy, non-declining adults. Almost nothing has credible evidence for this. The few ingredients with human RCT data for cognition have that data in older adults, in people with age-associated memory impairment, or in populations with nutritional deficiencies. That evidence does not transfer to a healthy 30-year-old seeking a mental edge.

Cognitive protection means slowing the rate of decline, preserving function longer, or reducing risk of progression in people who are already experiencing early cognitive changes or who have known risk factors (elevated homocysteine, confirmed nutritional deficiency, vascular risk). Some ingredients have genuinely meaningful evidence in this population.

The same pattern recurs throughout: most benefits in this category are deficiency-correction effects or effects in impaired populations. B vitamins benefit people with elevated homocysteine. B12 benefits people with B12 deficiency. ALA benefits people with diabetic neuropathy. The evidence does not generalise to supplementing healthy, replete adults and expecting the same outcomes.

Brain and cognitive health — ingredients by evidence

The table below covers the main cognitive supplement ingredients. Evidence tiers reflect the quality of human clinical trial data for cognitive outcomes specifically. Positive effects in stress, mood, or anxiety are noted separately from cognitive effects.

Nerve health — where supplement evidence is actually strongest

The nerve health supplement evidence base is substantially more developed than the cognitive supplement evidence base — but only for one specific condition: diabetic peripheral neuropathy (DPN). This distinction matters enormously for marketing accuracy, because most 'nerve support' supplements are sold to a general audience rather than to people with diagnosed DPN.

Diabetic peripheral neuropathy affects approximately 50% of people with long-standing diabetes and involves progressive damage to peripheral sensory and motor nerves, presenting as burning pain, tingling, numbness, and loss of sensation in the feet and hands. Several supplements have genuine clinical trial data in this population.

Non-diabetic neuropathy — including idiopathic neuropathy, chemotherapy-induced neuropathy, and hereditary neuropathies — has a much thinner supplement evidence base. Evidence from diabetic neuropathy trials should not be assumed to generalise to these conditions.

Safety concerns specific to this category

The most counterintuitive safety issue in this entire guide is vitamin B6 — an ingredient in almost every 'nerve support' formula.

• Vitamin B6 (pyridoxine) neuropathy — as above; doses above 50mg/day over months carry documented risk; the 'nerve support' category has a specific risk of products worsening what they claim to treat
• ALCAR and TMAO cardiovascular signal — L-carnitine supplementation is metabolised by gut bacteria to trimethylamine (TMA), which is oxidised to TMAO (trimethylamine N-oxide) — a metabolite associated with cardiovascular risk in observational studies. The clinical significance of ALCAR-derived TMAO elevation is not fully established, but it is a plausible concern for long-term use in people with cardiovascular risk factors
• Ginkgo biloba and anticoagulants — ginkgo inhibits platelet-activating factor; interaction with warfarin, clopidogrel, and aspirin is clinically relevant; should be discontinued two weeks before elective surgery
• Ashwagandha and thyroid hormones — multiple case reports and small studies link ashwagandha supplementation to elevated thyroid hormone levels; people with thyroid conditions or on thyroid medication should exercise caution and monitor thyroid function
• Ashwagandha and hepatotoxicity — rare but documented cases of drug-induced liver injury (DILI) associated with ashwagandha supplementation have been published in case reports (PMC). The risk appears low but is not zero; avoid in patients with liver disease or on hepatotoxic medications
• Curcumin and anticoagulants — high-bioavailability curcumin (Theracurmin, BCM-95) inhibits platelet aggregation and CYP450 enzymes that process warfarin; clinically relevant interaction in patients on blood thinners
• High-dose ALA and biotin competition — alpha lipoic acid at doses above 600mg/day competitively inhibits biotin-dependent enzymes; relevant for people taking high-dose biotin (hair/nail supplements often contain 5,000–10,000 mcg biotin)
• Ginkgo seizure risk — ginkgo has been associated with lowering seizure threshold in case reports; people with epilepsy or on seizure medications should avoid it

Red flags specific to this category

• Claiming to prevent or reverse Alzheimer's disease — no supplement has demonstrated this in any rigorous trial; the GEM study (n=3,069, 6 years) showed ginkgo had no preventive effect; no supplement has done better
• Nootropic 'cognitive enhancement' claims for healthy young adults — the evidence base for cognitive supplements is almost entirely in older adults with memory complaints, MCI, or specific nutritional deficiencies; extrapolation to healthy adults seeking improved performance is not supported
• 'Repairs nerve damage' or 'regrows nerves' — no oral supplement has demonstrated peripheral nerve regeneration in adequately powered human trials; at best, supplements may reduce pain symptoms or slow progression in diabetic neuropathy
• Pineal gland detox or 'decalcification' language — the pineal gland does accumulate calcium fluoride with age (corpora arenacea), but there is no clinical evidence that this calcification causes cognitive problems treatable by supplements, and no evidence that any supplement decalcifies it; this is pseudoscientific marketing
• B-vitamin blends with undisclosed doses — given the B6 toxicity risk, any nerve supplement that does not disclose the exact milligrams of pyridoxine per serving should not be purchased; proprietary blends for nerve health are specifically dangerous if B6 is included
• Generic 'mushroom blend' without Lion's Mane specified — the NGF-stimulating compounds (hericenones and erinacines) are specific to Hericium erinaceus; generic mushroom blends (reishi, chaga, shiitake, turkey tail) have no equivalent nerve or cognitive mechanism
• Non-diabetic neuropathy claims using diabetic neuropathy evidence — SYDNEY, BENDIP, and ALADIN trials were conducted in diabetes patients; claiming these results apply to idiopathic neuropathy, chemotherapy-induced neuropathy, or general nerve health misrepresents the evidence
• Formulas combining 15+ ingredients at undisclosed doses — ALA requires 600mg, benfotiamine requires 600mg, ALCAR requires 1,500–3,000mg; a 'complete nerve support' formula in 2 capsules containing all of these plus ten other ingredients cannot contain effective doses of any of them
• Using the FDA qualified health claim for phosphatidylserine as evidence of efficacy — the FDA qualified health claim (used by PS since 2003) means the evidence was reviewed but found limited and inconsistent; it is the lowest FDA evidence tier and explicitly not an endorsement of efficacy